Key Review Findings
Nucleic Acid Detection
- Biosensing platforms leveraging this dual approach can achieve ultrasensitive detection of targets like viral genomes and cancer biomarkers at attomolar concentrations.
- For example, a novel chemiluminescence biosensor (CRISPR-CXCLAmp) utilizing quadruple amplification achieved a limit of detection of 16 aM for the biomarker miRNA-21.
Protein and Cell Detection
- CRISPR technology can effectively improve protein detection sensitivity by coupling with aptamers to convert non-nucleic acid targets into nucleic acid signals.
- Pathogen detection, such as for Escherichia coli O157:H7, was achieved using an electrochemical biosensor combining CRISPR/Cas12a and immuno-RCA, providing sensitive detection without complex pre-amplification steps.
Small-Molecule and In Situ Detection
- These biosensing strategies are expanding to small molecules (like aflatoxin and pesticide residues) by using target converters and aptamers to trigger Cas protein cleavage.
- Due to its excellent biocompatibility, RCA is particularly suitable for in situ detection, allowing for the visualization of RNA and DNA within single cells and tissues.
Technological Implications
These biosensors offer transformative potential for diverse applications, including clinical diagnostics, environmental monitoring, and food safety. By enabling rapid, isothermal amplification and detection with minimal equipment, this synergy enables:
- Cost-Effective POCT: Integration with smartphone-based fluorescence detectors and microfluidic paper-based chips to significantly reduce testing costs while maintaining high accuracy.
- Simplified Workflows: The development of one-pot isothermal assays that leverage Cas cleavage to minimize complex operating steps and reduce the risk of contamination.
- Ultrasensitive Field Deployment: Delivering near-laboratory-grade accuracy in portable formats, outperforming traditional lateral flow assays in sensitivity and specificity.
Challenges and Future Directions
While these CRISPR-RCA systems bridge a critical gap and rival existing "gold standards," several challenges remain before widespread commercialization:
- Cost Reduction: Addressing the high costs associated with specific instruments, CRISPR/Cas proteins, and RCA reagents.
- Portability Balance: Seeking an optimal balance between device portability and detection sensitivity.
- Standardization: Establishing rigorous optimization of reaction conditions (such as temperature uniformity and reagent formulations) to ensure reproducible performance in field settings.
Future research should prioritize the exploration of new Cas proteins, the digitalization of CRISPR systems to improve detection limits, and the integration of emerging engineering strategies like miniaturized microfluidic platforms.
Toward a CRISPR-RCA POCT Future
This review demonstrates that the synergy of RCA and CRISPR/Cas systems exhibits high sensitivity and specificity, making these platforms highly versatile for diagnostic applications. By overcoming current commercial barriers, these advanced biosensing tools have the enormous potential to step out of the laboratory and enter our daily lives, significantly enhancing medical diagnosis, disease management, and smart healthcare.